Genome-wide association analyses of sleep disturbance traits identify new loci and highlight shared genetics with neuropsychiatric and metabolic traits by Lane, Jacqueline M. et al.
Genome-wide association analyses of sleep disturbance traits identify new loci and 1 
highlight shared genetics with neuropsychiatric and metabolic traits 2 
Jacqueline M. Lane1, 2, 3, Jingjing Liang4, Irma Vlasac1,3, Simon G. Anderson5,6, David A. 3 
Bechtold7,8, Jack Bowden9,10, Richard Emsley11, Shubhroz Gill3, Max A. Little12,13, AnneMarie I. 4 
Luik 14, Andrew Loudon7,8, Frank A.J.L. Scheer15, Shaun M. Purcell3,16,17, Simon D. Kyle14, 5 
Deborah A. Lawlor9,10, Xiaofeng Zhu4, Susan Redline18, David W. Ray7,8, Martin K. Rutter 7,8,19*, 6 
Richa Saxena1,2,3,15* 7 
 8 
*Equal Contribution 9 
 10 
1Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, USA 11 
2Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital 12 
and Harvard Medical School, Boston, MA, USA 13 
3Broad Institute, Cambridge, MA, USA 14 
4Department of Epidemiology and Biostatistics, School of Medicine, Case Western Reserve 15 
University, Cleveland, OH 44106, USA. 16 
5Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine 17 
and Health, The University of Manchester, Manchester, UK 18 
6The George Institute for Global Health, University of Oxford, Oxford Martin School, 34 Broad 19 
Street Oxford OX1 3BD, UK 20 
7Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK 21 
8Division of Endocrinology, Diabetes & Gastroenterology, School of Medical Sciences, Faculty 22 
of Biology, Medicine and Health, University of Manchester, UK 23 
9MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK 24 
10School of Social and Community Medicine, University of Bristol, Bristol, UK 25 
11Division of Population Health, Health Services Research and Primary Care, School of Health 26 
Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester 27 
Academic Health Science Centre, Manchester, UK 28 
12Engineering and Applied Science, Aston University, Birmingham, UK 29 
13Media Lab, Massachusetts Institute of Technology, Cambridge, MA, USA 30 
14Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, 31 
University of Oxford, Oxford, UK 32 
15Division of Sleep and Circadian Disorders, Brigham and Women’s Hospital, and Division of 33 
Sleep Medicine, Harvard Medical School, Boston, MA, USA 34 
16Department of Psychiatry, Brigham and Women’s Hospital, Harvard Medical School, Boston, 35 
MA. 36 
17Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York. 37 
18Departments of Medicine, Brigham and Women's Hospital and Beth Israel Deaconess Medical 38 
Center, Harvard Medical School, Boston 39 
19Manchester Diabetes Centre, Central Manchester University Hospitals NHS Foundation Trust, 40 
Manchester Academic Health Science Centre, Manchester, UK 41 
 42 
Corresponding author 43 
R. Saxena, Center for Human Genetic Research, Massachusetts General Hospital,  44 
185 Cambridge Street, CPZN 5.806,  45 
Boston, MA, 02114, USA  46 
E-mail: rsaxena@partners.org  47 
Phone: 617-643-8578  48 
Fax: 617-643-3203 49 
 50 
Word count: 1923 51 
Table count: 2 52 
Figure count: 4 53 
Supp count: Tables 12/ Figures 8 54 
  55 
Chronic sleep disturbances, associated with cardio-metabolic diseases, psychiatric disorders 56 
and all-cause mortality1,2, affect 25-30% of adults worldwide3. While environmental factors 57 
contribute importantly to self-reported habitual sleep duration and disruption, these traits are 58 
heritable4-9, and gene identification should improve our understanding of sleep function, 59 
mechanisms linking sleep to disease, and development of novel therapies.  We report single 60 
and multi-trait genome-wide association analyses (GWAS) of self-reported sleep duration, 61 
insomnia symptoms including difficulty initiating and/or maintaining sleep, and excessive 62 
daytime sleepiness in the UK Biobank (n=112,586), with discovery of loci for insomnia 63 
symptoms (near MEIS1, TMEM132E, CYCL1, TGFBI in females and WDR27 in males), 64 
excessive daytime sleepiness (near AR/OPHN1) and a composite sleep trait (near INADL and 65 
HCRTR2), as well as replication of a locus for sleep duration (at PAX-8). Genetic correlation 66 
was observed between longer sleep duration and schizophrenia (rG=0.29, p=1.90x10-13) and 67 
between increased excessive daytime sleepiness and increased adiposity traits (BMI rG=0.20, 68 
p=3.12x10-09; waist circumference rG=0.20, p=2.12x10-07).  69 
 70 
Rather than being ‘secondary’, evidence suggests disordered sleep may play an important role 71 
in the etiology and maintenance of physical and mental health1,2. Heritability has been estimated 72 
at ~40% for sleep duration4,6-8, 25-45% for insomnia9 and 17% for excessive daytime 73 
sleepiness9, but few genetic factors are known. A Mendelian short sleep mutation in BHLHE41 74 
(P385R) has been identified, and confirmed in mouse models10. GWAS for sleep duration have 75 
been reported11-14, but only an association at the PAX8 locus reached genome-wide significance 76 
and was confirmed across ethnic groups12.  There are several reported loci for restless legs 77 
syndrome (RLS) and narcolepsy, but no known robust genetic loci for insomnia symptoms or  78 
excessive daytime sleepiness15,16.  79 
 80 
We and others performed a GWAS for chronotype in the UK Biobank17,18 and a 23&me 81 
participant sample19. To identify genetic variants that contribute to self-reported sleep duration, 82 
insomnia symptoms, and excessive daytime sleepiness and link them with other conditions, we 83 
performed GWAS using phenotype measures in UK Biobank participants of European ancestry. 84 
Variation in sleep duration, insomnia symptoms and excessive daytime sleepiness was 85 
associated significantly with age, sex, principal components of ancestry (PCs), genotyping 86 
array, depression, psychiatric medication use, self-reported sleep apnea, and BMI 87 
(Supplementary Table 1), as previously reported20-23. Together age, sex, and PCs explained 88 
0.4%, 3.0% and 1.3% of variation in sleep duration, insomnia symptoms, and excessive daytime 89 
sleepiness respectively.  Strong and significant pair-wise phenotypic correlation was seen 90 
between the traits overall and within each sex, with limited correlation observed with 91 
chronotype. (Fig. 1a; Supplementary Fig. 1).  92 
 93 
GWAS analyses of sleep duration, insomnia symptoms and excessive daytime sleepiness were 94 
performed using linear/logistic regression adjusting for age, sex, 10 PCs and genotyping array. 95 
Nine genome-wide significant (p<5x10-8) and 14 suggestive (p<5x10-7 to p=5x10-8) loci were 96 
identified (Fig. 2, Table 1, Supplementary Figs. 2 and 3). For sleep duration (n=111,975), the 97 
strongest association was observed at the PAX-8 locus (rs62158211T, β(se)=2.34(0.30) 98 
mins/allele, p=4.7x10-14, effect allele frequency (EAF) 0.213, Fig. 2a), confirming a previously 99 
reported association (r2=0.96, D’=1 to lead SNP rs1823125 in 1KG CEU)12. For insomnia 100 
symptoms (n=32,155 cases, 26,973 controls), significant associations were observed within 101 
MEIS1 (rs113851554T, OR [95%CI]=1.26[1.20-1.33], p=9.1x10-19, EAF 0.057, Fig. 2b), a 102 
homeobox gene implicated in motor neuron connectivity in Drosophila24,25, retinal and lens 103 
development in mouse26, and Substance P expression in the amygdala27, near TMEM132E 104 
(rs145258459C, 1.23[1.13-1.35], p=2.1x10-8, EAF 0.983, Fig. 2c), a gene family with roles in 105 
brain development28, panic/anxiety29 and bipolar disorder30, suggesting a link between insomnia 106 
symptoms and an underlying broader sensitivity to anxiety and stress, and near CYCL1 107 
(rs5922858G, OR [95%CI]=1.12[1.07-1.16], p=1.28 x10-8, EAF 0.849, Fig 2d) a locus previously 108 
associated (p=10-6) with alcohol dependence co-morbid with depressive symptoms31. Sex-109 
stratified analyses identified an additional female-specific signal near TGFBI (rs3792900C 110 
1.10[1.07-1.14], p=2.16x10-8, EAF 0.470; Table 1, Supplementary Fig. 3q, 3r, Supplementary 111 
Table 2), an extracellular matrix protein responsible for human corneal dystrophy32 and a male-112 
specific signal near WDR27, a scaffold protein (rs13192566G OR [95%CI]=1.14[1.09-1.20], 113 
p=3.2x10-8, EAF 0.860)(Table 1, Supplementary Fig. 3s, 3t, 4; Supplementary Table 2). 114 
Independent associations at both loci are observed with type 1 diabetes, suggesting an immune 115 
role33-35. For excessive daytime sleepiness (n=111,648), we identified a signal near the 116 
androgen receptor AR (rs73536079T, β=0.634, p=3.94x10-8, EAF 0.002, Fig. 3e), with no sex-117 
specific effects.  Secondary analyses after additional adjustment for depression or BMI identified 118 
a signal near ROBO1,  (depression adjustment n=107,440, rs182765975T, beta=0.099, 119 
p=3.33x10-8, EAF 0.003, Table 1, Supplementary Figure 3o), a neuronal axon guidance 120 
receptor previously implicated in dyslexia36, and a signal near another member of the TMEM132 121 
family, TMEM132B (BMI adjustment n=75,480, rs142261172A, β=0.106, p=9.06x10-9, EAF 122 
0.004, Table 1, Supplementary Figure 3p).  Conditional analyses did not identify independent 123 
association signals (Supplementary Table 3). Sensitivity analyses adjusting for factors 124 
influencing sleep traits, including self-reported sleep apnea, depression, psychiatric medication 125 
use, smoking, socio-economic status, employment status, marital status, and snoring did not 126 
significantly alter results for primary association signals (Supplementary Table 4).  127 
 128 
The leading associations overlap interesting candidate genes enriched in murine/zebrafish 129 
hypocretin expressing neurons37,38, differentially expressed in sleep-deprived rats39, and/or 130 
regulate sleep in Drosophila40. Credible set analyses41 highlighted a number of potential causal 131 
variants at each locus (Table 1) and future experimental studies will be necessary.  132 
Bioinformatic annotations42 offer an initial opportunity at in silico functional interpretation 133 
(Supplementary Table 5; Supplementary Fig. 5). For example, multiple variants for all three 134 
traits are predicted to disrupt binding of FOXP1, a neural transcriptional repressor implicated in 135 
intellectual disability, autism and language impairment43. Interestingly, the PAX-8 sleep duration 136 
association is adjacent to the only chromosomal fusion site since divergence of humans from 137 
other hominids ~5 million years ago44,45, and the novel genomic structure created by this unique 138 
evolutionary history may play a causal role. Pathway analysis46 of significant and suggestive loci 139 
revealed enrichment of genes associated with immune, neuro-developmental, pituitary and 140 
communication disorders (p<0.01), and enriched for transcription factor-binding sites for stress-141 
responsive heat-shock-factor 1 (HSF1) and endoplasmic reticulum stress/unfolded protein-142 
responsive factor HERPUD1 (Supplementary Tables 6&7).  143 
 144 
Aside from the lead PAX-8 SNPs and a DRD2 region variant47 for sleep duration, limited 145 
evidence of association was observed for previously published candidate gene or GWAS 146 
signals (pmeta<5x10-5; Supplementary Table 8), or for regions encompassing core clock genes 147 
(Supplementary Fig. 6). Our findings for sleep duration GWAS largely overlap with Jones et 148 
al.18, despite differences in exclusion criteria and analytic approach. Particularly, our study 149 
excluded shift workers (n=6,557), sleep medication users (n=1,184) and first-to-third degree 150 
relatives (n=7,980), whereas the linear mixed-model analyses by Jones et al. included these 151 
populations, leading to a larger sample size (n=127,573). Likely due to this increase in power, 152 
Jones et al. identified two additional signals at VRK2 that did not attain genome-wide 153 
significance in our study (rs1380703A β(se)=1.5(0.30) mins/allele, p=8.43x10-8 and 154 
rs17190618T, β(se)=1.60(0.34) mins/allele, p=3.80x10-6). 155 
 156 
Trait heritability calculated as the proportion of trait variance due to additive genetic factors 157 
measured here (observed scale SNP heritability, h2 (S.E.)) was 10.3 (0.006)% for sleep 158 
duration, 20.6 (0.011)% for insomnia symptoms and 8.4 (0.006)% for sleepiness (BOLT-REML 159 
variance components analysis48). LD-score regression analysis49 confirmed no residual 160 
population stratification (Intercept (SE): Sleep Duration 1.012 (0.008), Insomnia Symptoms 161 
1.003 (0.008), Excessive Daytime Sleepiness 1.005 (0.007).   Tests for enrichment of heritability 162 
by functional class using an LD-score regression approach50 identified excess heritability across 163 
active transcriptional regions for insomnia symptoms and genomic regions conserved in 164 
mammals for all three sleep traits.  Consistently, heritability enrichment in conserved regions 165 
was seen for traits demonstrating significant genetic correlation with sleep (Fig. 3, 166 
Supplementary Table 9).  167 
 168 
Sleep duration, insomnia symptoms, excessive daytime sleepiness, and chronotype, are 169 
significantly correlated both at the phenotype and genetic level (Fig. 1), with greater pair-wise 170 
correlations in males as compared to females (Supplementary Fig.1). Thus, in order to find loci 171 
common to sleep traits, we performed a multi-trait GWAS51.  We identified two novel association 172 
signals near HCRTR2 and INADL, and revealed that PAX-8 and MEIS-1 associations influence 173 
multiple sleep traits (Fig. 2; Table 2, Supplementary Fig. 7). HCRTR2 encodes hypocretin 174 
receptor 2, the main receptor of two receptors for wake-promoting orexin neuropeptides52 175 
involved in narcolepsy and regulation of sleep. Notably, the minor allele at rs3122163 (C) 176 
showed sub-threshold association with shorter sleep duration and morningness chronotype, 177 
suggesting gain of function, but no association with insomnia symptoms. Assessment of 178 
objective sleep measures, functional and physiologic follow-up should yield important insights 179 
into orexin receptor signaling, a pathway important for the pharmacological treatment of 180 
narcolepsy53 and insomnia54.  INADL encodes a membrane protein involved in the formation of 181 
tight junctions, and is implicated in photoreception in mice and Drosophila55,56. The INADL 182 
protein is reported to interact with HTR2A57, a serotonin receptor with a known role in sleep 183 
regulation58,59.    184 
 185 
Our strongest association for insomnia symptoms fell within MEIS1, a locus previously 186 
associated with RLS in GWAS60. Our lead SNP rs113851554 and the correlated 3’UTR variant 187 
rs11693221 (pair-wise r2=0.69, D’=0.90 in 1KG EUR) represent the strongest known genetic risk 188 
factor for RLS and were identified in follow-up sequencing studies of MEIS161,62 of the original 189 
RLS GWAS signal rs230047860,63. Conditional analysis suggests that only one underlying signal 190 
detected by the lead SNP rs113851554 in our GWAS explains the association of all three SNPs 191 
with insomnia symptoms (Supplementary Fig. 8; Supplementary Table 10). To further 192 
investigate the extent of overlap between RLS and insomnia symptoms, we tested if a  weighted 193 
genetic risk score (GRS) for RLS64,65 was also associated with insomnia symptoms with 194 
concordant direction of allelic effects (OR [95%CI]= 1.06[1.05-1.07] per RLS risk allele, 195 
p=1.17x10-21; Supplementary Table 11). Weighting of RLS GWAS alleles by SNP effects on 196 
periodic limb movements (PLMs) did not substantially alter overall results (Supplementary 197 
Table 11). Interestingly, recent data indicating increased thalamic glutamatergic activity in RLS 198 
provides evidence for an underlying propensity for hyperarousal in RLS66, which is also a core 199 
feature of insomnia. Future analyses of pair-wise bidirectional causal effects for all three traits 200 
will be necessary to determine if shared genetic associations represent causality, partial 201 
mediation or pleiotropy. 202 
Strong epidemiologic associations of sleep duration, insomnia symptoms and sleepiness have 203 
been observed with disease traits, but the extent to which the underlying genetics is shared is 204 
unknown. Therefore, we tested for genome-wide genetic correlation between our sleep GWAS 205 
and publicly available GWAS for 20 phenotypes spanning a range of cognitive, 206 
neuropsychiatric, anthropometric, cardio-metabolic and auto-immune traits using LD-score 207 
regression67 (Fig. 4 and Supplementary Table 12).  208 
 209 
Genetic correlations demonstrated a strong biological link between longer sleep duration and 210 
risk of schizophrenia (rG=0.29, p=10-13), as suggested by previous reports18,47,68. Furthermore, a 211 
schizophrenia GRS (96 variants) was associated with longer sleep duration (β(se)=1.44(0.36) 212 
mins/allele, p=2.56x10-4 [2.3 hr inter-quartile range], although a variety of sleep behaviors are 213 
seen in schizophrenia patients69-71. Significant genetic correlation between low birth weight and 214 
longer sleep duration (rG= -0.27, p=10-4) may reflect shared links between genetically-215 
determined insulin secretion or action pathways underlying fetal growth72,73 and long sleep 216 
duration. In support, significant genetic correlation was observed by Jones et al.18 between 217 
over-sleepers and both fasting insulin and risk of type 2 diabetes in UK Biobank. Genetic 218 
correlation between sleep duration and Crohn’s disease risk (rG=0.18, p=10-3) is also consistent 219 
with epidemiologic observations74.  220 
 221 
Significant genetic correlation was also found between increased insomnia symptoms and major 222 
depression, adverse glycemic traits, increased adiposity and fewer years of education, and 223 
between excessive daytime sleepiness and increased adiposity (all p<10-3), further highlighting 224 
biological overlap of sleep traits with metabolism, psychiatric traits, and educational 225 
attainment17. In support, studies have shown that experimentally suppressing slow wave sleep 226 
leads to decreased insulin sensitivity and impaired glucose tolerance75,76. Notably, a fasting 227 
insulin GRS was not significantly associated with insomnia symptoms (7 SNPs, OR =1.01, 228 
p=0.51). Finally, consistent with a well-established but poorly-understood link between 229 
excessive daytime sleepiness and obesity77,78, a BMI GRS was associated with excessive 230 
daytime sleepiness (95 SNPs, β(se) 0.002(0.0004) sleepiness category/allele, p=1.67x10-4), but 231 
not with insomnia symptoms (OR=1.00, p=0.73).  232 
 233 
Moving forward, replication and systematic testing of genetic correlations in larger samples will 234 
be needed. Importantly, genetic correlation testing between insomnia and RLS should be 235 
examined, but was not possible here because RLS consortium GWAS results were not 236 
available. Additionally, identifying causal relationships between genetically correlated traits may 237 
be difficult, and findings using Mendelian randomization approaches will need cautious 238 
interpretation given potential selection biases in UK Biobank79-81.  239 
 240 
In summary, in a GWAS of sleep traits, we identified new genetic loci that point to previously 241 
unstudied variants might modulate the hypocretin/orexin system, retinal development, and 242 
influence cerebral cortex genes. Furthermore, genome-wide analysis suggests that sleep traits 243 
share underlying genetic pathways with neuropsychiatric and metabolic disease. This work 244 
should advance understanding of molecular processes underlying sleep disturbances, and open 245 
new avenues of treatment for sleep disorders and related disorders  246 
 247 
 248 
Methods 249 
Population and study design 250 
Study participants were from the UK Biobank study, described in detail elsewhere80-82.  In brief, 251 
the UK Biobank is a prospective study of >500,000 people living in the United Kingdom.  All 252 
people in the National Health Service registry who were aged 40-69 and living <25 miles from a 253 
study center were invited to participate between 2006-2010.  In total 503,325 participants were 254 
recruited from over 9.2 million mailed invitations.  Self-reported baseline data was collected by 255 
questionnaire and anthropometric assessments were performed.  For the current analysis, 256 
individuals of non-white ethnicity were excluded to avoid confounding effects.  All participants 257 
provided informed consent to the UK Biobank.   258 
 259 
Sleep quality, quantity and covariate measures 260 
Study subjects self-reported sleep duration, insomnia symptoms, excessive daytime sleepiness, 261 
depression, medication use, age, sex, height and weight on a touch-screen questionnaire.  For 262 
sleep duration, subjects were asked, “About how many hours sleep do you get in every 24 263 
hours? (please include naps)?”  with responses in hour increments.  To assess insomnia 264 
symptoms, subjects were asked, “Do you have trouble falling asleep at night or do you wake up 265 
in the middle of the night?" with responses “never/rarely”, “sometimes”, “usually”, “prefer not to 266 
answer”.  To assess daytime sleepiness, subjects were asked “How likely are you to doze off or 267 
fall asleep during the daytime when you don't mean to? (e.g. when working, reading or 268 
driving)?" with responses “never/rarely”, “sometimes”, “often”, “all the time”, “don’t know”, “prefer 269 
not to answer”.  Approximately 500,000 subjects answered these questions, but only the 270 
120,286 unrelated individuals with genetic data and European ancestry were considered for this 271 
analysis.  Subjects with self-reported shift work (n=6,557) or sleep medication use (n=1,184) 272 
were excluded.  Subjects who responded “Do not know” or “Prefer not to answer” were set to 273 
missing.  Sleep duration and excessive daytime sleepiness were untransformed and treated as 274 
continuous variables, with daytime sleepiness coded 1-4.  The insomnia symptom trait was 275 
dichotomized into controls (“never/rarely”) and cases (“usually”).  Covariates used in sensitivity 276 
analyses included self-reported sleep apnea, BMI, depression, psychiatric medication use, 277 
socio-economic, smoking, employment and marital status, and snoring, and secondary GWAS 278 
for sleepiness included adjustment for BMI or depression. Sleep apnea cases were defined 279 
based on ICD10 diagnosis code (391 cases). BMI at baseline visit was calculated from entries 280 
of height and weight (n=75,540 with available data). Depression was reported in answer to the 281 
question “How often did you feel down, depressed or hopeless mood in last 2 weeks?” (cases, 282 
n=4,242 based on answers “more than half the days”, or “nearly every day”). Medication use 283 
was self-reported as part of the initial UK Biobank interview.  Our list of psychiatric medication 284 
for sensitivity analysis included the four most widely used: fluoxetine (Prozac), citalopram 285 
(Cipranol), paroxetine (Seroxat), and sertraline (Lustral).  Our list of sleep medications included 286 
the 21 most widely used sleep medications in the UK Biobank: oxazepam, meprobamate, 287 
medazepam, bromazepam, lorazepam, clobazam, chlormezanone, temazepam, nitrazepam, 288 
lormetazepam, diazepam, zopiclone, triclofos, methyprylone, prazepam, triazolam, ketazolam, 289 
dichloralphenazone, clomethiazole, zaleplon, butobarbital.  Smoking status was self-reported as 290 
past smoking behavior and current smoking behavior, and classified into “current”, “past”, or 291 
“never” smoked.  Socio-economic status was represented by the Townsend deprivation index, 292 
based on national census data immediately preceding participation in the UK Biobank.  293 
Employment status was self-reported (cases=retired, controls=currently employed).  Marital 294 
status was derived from self-reported household occupancy and relatedness data.  Snoring was 295 
reported in answer to the question “Does your partner or a close relative or friend complain 296 
about your snoring?”.   297 
Genotyping, quality control and imputation 298 
Of the ~500,000 subjects with phenotype data in the UK Biobank, ~153,000 are currently 299 
genotyped.  Genotyping was performed by the UK Biobank, and genotyping, quality control, and 300 
imputation procedures are described in detail at the UK Biobank website 301 
(http://biobank.ctsu.ox.ac.uk/).  In brief, blood, saliva, and urine was collected from participants, 302 
and DNA was extracted from the buffy coat samples.  Participant DNA was genotyped on two 303 
arrays, UK BiLEVE and UKB Axiom with >95% common content.  Genotypes were called using 304 
Affymetrix Power Tools software.  Sample and SNP quality control were performed.  Samples 305 
were removed for high missingness or heterozygosity (480 samples), short runs of 306 
homozygosity (8 samples), related individuals (1,856 samples), and sex mismatches (191 307 
samples).  Genotypes for 152,736 samples passed sample QC (~99.9% of total samples).  308 
SNPs were excluded if they did not pass QC filters across all 33 genotyping batches.  Batch 309 
effects were identified through frequency and Hardy-Weinberg equilibrium tests (p-value <10-12). 310 
Before imputation, 806,466 SNPs pass QC in at least one batch (>99% of the array content).  311 
Population structure was captured by principal component analysis on the samples using a 312 
subset of high quality (missingness <1.5%), high frequency SNPs (>2.5%) (~100,000 SNPs) 313 
and identified the sub-sample of European descent.   Imputation of autosomal SNPs was 314 
performed to a merged reference panel of the Phase 3 1000 Genome Project and the UK10K 315 
using IMPUTE283.  Data were prephased using SHAPEIT384. In total, 73,355,677 SNPs, short 316 
indels and large structural variants were imputed.  X-chromosome data were imputed 317 
separately, using Eagle 2.0 for pre-phasing with the –X chromosome flag (no reference panel) 318 
in the entire cohort85 and IMPUTE283 with the Phase 3 1KG Project reference panel for 319 
imputation using the –chrX flag on 500kb chunks in randomly assigned subsets of 30,000 320 
individuals.  Post-imputation QC was performed as previously outlined 321 
(http://biobank.ctsu.ox.ac.uk/) and an imputation info score cut-off of 0.8 was applied. For 322 
GWAS, we further excluded SNPs with MAF <0.001, maximum per SNP missingness of 10%, 323 
and maximum per sample missingness of 40%.  In total, up to 112,586 samples of European 324 
descent with high quality genotyping and complete phenotype/covariate data were used for 325 
these analyses. 326 
Statistical Analysis 327 
Phenotypic correlation analysis was performed using the Spearman test in R using the Hmisc 328 
package.  Genetic association analysis for autosomes was performed in SNPTEST86,87 with the 329 
“expected” method using an additive genetic model adjusted for age, sex, 10 PCs and 330 
genotyping array.  Genome-wide association analysis was performed separately for sleep 331 
duration, insomnia symptoms, and excessive daytime sleepiness with a genome-wide 332 
significance threshold of 5x10-8 for each GWAS.  We are 80% powered to detect the following 333 
effects: sleep duration β=0.045 hrs (2.7 mins), insomnia symptoms OR=1.07, and excessive 334 
daytime sleepiness β=0.021 units (assuming a MAF 0.1, p=5x10-7) and 80% powered to detect 335 
the following effects: sleep duration β= 0.048 hrs (2.9 mins), insomnia symptoms OR=1.08 and 336 
excessive daytime sleepiness β=0.023 units (assuming a MAF 0.1, p=5x10-8).  X-chromosome 337 
analysis was performed in PLINK 1.988 using linear/logistic regression with separate analysis 338 
of the pseudoautosomal regions using the split chromosome flag, adjusting for sex, age, 10 PCs 339 
and genotyping array. For the X chromosome signal at rs73536079, we verified using principal 340 
components analysis that all carriers of the minor allele fall within the major European ancestry 341 
cluster.  Follow-up analyses on genome-wide suggestive and significant loci in the primary 342 
analyses included covariate sensitivity analysis individually adjusting for sleep apnea, 343 
depression, psychiatric medication use, socio-economic, smoking, employment and marital 344 
status, and snoring, or BMI (on top of the baseline model adjusting for age, sex, 10 PCs and 345 
genotyping array).  Sensitivity analysis was conducted only in the subset of subjects with all 346 
secondary covariates (n=75,477 for sleep duration, n=39,812 for insomnia symptoms and 347 
n=75,640 for excessive daytime sleepiness). Enrichment for disease associated gene sets and 348 
transcription factors was performed in WebGestalt46 using the human genome as the reference 349 
set, the Benjamini Hochberg adjustment for multiple testing, and a minimum number of 2 genes 350 
per category. Sex specific GWAS were performed in PLINK 1.988 using linear/logistic regression 351 
stratified by sex adjusting for age, 10 principal components of ancestry, and genotyping array.  352 
We used a hard-call genotype threshold of 0.1 (calls with greater than 0.1 are treated as 353 
missing), SNP imputation quality threshold of 0.80, and a MAF threshold of 0.001.  Regional 354 
association plots were made using Locuszoom with the HG19 Nov2014 EUR reference panel 355 
for background linkage disequilibrium89.  356 
Trait heritability was calculated as the proportion of trait variance due to additive genetic factors 357 
across the autosomes measured in this study using BOLT-REML48, to leverage the power of 358 
raw genotype data together with low frequency variants (MAF≥0.001). For multi-trait genome-359 
wide association analysis we applied the CPASSOC package developed by Zhu et al.51 to 360 
combine association evidence of chronotype, sleep duration, insomnia symptoms and excessive 361 
daytime sleepiness. CPASSOC provides two statistics, SHom and SHet. SHom is similar to the 362 
fixed effect meta-analysis method90 but accounting for the correlation of summary statistics 363 
because of the correlated traits. SHom uses a sample size of a trait as a weight instead of 364 
variance, so that it is possible to combine traits with different measurement scales. SHet is an 365 
extension of SHom but power can be improved when the genetic effect sizes are different for 366 
different traits. The distribution of SHet under the null hypothesis was obtained through an 367 
estimated beta distribution. To calculate statistics SHom and SHet, a correlation matrix is 368 
required to account for the correlation among traits or induced by overlapped or related samples 369 
from different cohorts. In this study, we directly provide the correlation matrix calculated from the 370 
residuals of four sleep traits after adjusting for age, sex, PCs of ancestry and genotyping array. 371 
Post-GWAS genome-wide genetic correlation analysis of LD Score Regression (LDSC)67 was 372 
conducted using all UK Biobank SNPs also found in HapMap389 and included publicly available 373 
data from 20 published genome-wide association studies, with a significance threshold of 374 
p=0.0026 after Bonferroni correction for all 20 tests performed. As expected, the observed 375 
heritability estimates from LDSC67 using summary statistics for HapMap3 are lower (5.7 376 
(0.0065)% for sleep duration, 13.3 (0.0123)% for insomnia symptoms and 5.3 (0.005)% for 377 
sleepiness) than those calculated by Bolt-REML48 using primary data (10.3 (0.006)% for sleep 378 
duration, 20.6 (0.011)% for insomnia symptoms and 8.4 (0.006)% for sleepiness), because the 379 
HapMap3 panel restricts to variants with >5% MAF. LDSC estimates genetic correlation 380 
between two traits from summary statistics (ranging from -1 to 1) using the fact that the GWAS 381 
effect-size estimate for each SNP incorporates effects of all SNPs in LD with that SNP, SNPs 382 
with high LD have higher X2 statistics than SNPs with low LD, and a similar relationship is 383 
observed when single study test statistics are replaced with the product of z-scores from two 384 
studies of traits with some correlation67. Furthermore, genetic correlation is possible between 385 
case/control studies and quantitative traits, as well as within these trait types.   We performed a 386 
weighted genetic risk score analysis using risk scores for restless legs syndrome, 387 
schizophrenia, body mass index, and fasting insulin.  Risk score SNPs passed the genome-388 
wide significance threshold (p<5x10−8) from recent large-scale genome-wide association studies 389 
and were present in the UK Biobank (restless legs syndrome 7 SNPs Supp Table 1165; 390 
schizophrenia 96 SNPs91; BMI 95 SNPs92; fasting insulin 7 SNPs93). Independent SNPs were 391 
identified and beta estimates recorded for calculation of the weighted risk score. The genetic 392 
risk score was calculated by summing the products of the risk allele count multiplied by the 393 
effect reported in the discovery GWAS paper.  The additive genotype model was used for all 394 
SNPs.  We performed partitioning of heritability using the 25 pre-computed functional 395 
annotations available through LDSC, which were curated from large-scale robust datasets50. 396 
Enrichment both in the functional regions and in an expanded region (+500bp) around each 397 
functional class was calculated in order to prevent the estimates from being biased upward by 398 
enrichment in nearby regions. The multiple testing threshold was determined using the 399 
conservative Bonferroni correction (p of 0.05/25 classes).  Summary GWAS statistics will be 400 
made available at the UK Biobank web site (http://biobank.ctsu.ox.ac.uk/). 401 
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Table 1.  Genome-wide significant (p<5x10-8) and suggestive (p<5x10-7) loci associated with sleep duration, insomnia symptoms, and excessive daytime sleepiness in subjects of 
European ancestry in the UKBiobank. 
                        
Trait SNP  Chr:position 
NCBI 37 
Nearest Gene(s)  Alleles 
(E/A)  
EAF  Imputation 
Quality 
Beta 
(SE) 
  SE p-val 
 Most likely 
causal SNPs 
(probability)† 
Sleep Duration (n=111,975)         
  rs62158211 2:114106139 PAX8 T/G 0.213 0.99 0.039   0.005 4.72 x 10-14 
rs62158211 
(0.16), 
rs62158213 
(0.16), 
rs4618068 
(0.16), 
rs1807282 
(0.16), 
rs56093896 
(0.16) 
  rs1380703 2:57941287 VRK2/LOC647016/LOC100131953 A/G 0.618 0.89 0.025   0.005 8.44 x 10-8 rs1380703 (1) 
  rs10953765 7:114291435 FOXP2 G/A 0.447 0.98 0.022   0.004 2.96 x 10-7 
rs10953765 
(0.27), 
rs1456031 
(0.14) 
  rs146977851 10:56570954 PCDH15 C/T 0.971 0.97 0.065   0.013 3.53 x 10-7 
rs146977851 
(0.85), 
rs75334053 
(0.14) 
  rs61980273 14:94218949 PRIMA1/UNC79 A/G 0.039 1.00 0.058   0.011 1.30 x 10-7 rs61980273 (1) 
                        
Insomnia Symptoms (n up to 31,767 cases and 26,935 controls)       OR   95% CI     
                        
  rs576106307 1:18007282 ARHGEF10L C/CT 0.934 0.89 1.07   1.10-1.04 2.66 x 10-7 rs576106307 (1) 
  rs113851554 2:66750564 MEIS1 T/G 0.057 1.00 1.26   1.20-1.33 9.11 x 10-19 rs113851554 (0.98) 
  rs376775068 8:145604659 ADCK5 G/C 0.934 0.67 1.11   1.16-1.06 6.81 x 10-8 rs376775068 (1) 
  rs145258459 17:32986155 TMEM132E C/T 0.983 0.69 1.23   1.13-1.35 2.13 x 10-8 rs145258459 (1.0) 
  rs531814036 17:43219921 ACBD4 C/CT 0.419 0.91 1.06   1.03-1.08 2.92 x 10-7 rs531814036 
(1) 
  rs5922858 X:82971008 CYCL1 G/T 0.849 0.99 1.12   1.07-1.16 1.28 x 10-8 rs5922858 (1) 
Males rs13192566 6:169961635 WDR27 G/C 0.860 0.99 1.14   1.09-1.20 3.17 x 10-8 
rs13192566 
(0.50), 
rs13208844 
(0.50) 
Females rs3792900 5:135393754 TGFBI C/T 0.470 0.99 1.1   1.07-1.14 2.16 x 10-8 
rs3792900 
(0.14), 
rs6894815 
(0.07)  
                        
Excessive Daytime Sleepiness (n<111,648)         Beta   SE     
                        
  rs192315283 1:59531543 HSD52 C/T 0.010 0.76 0.126   0.025 3.55 x10-7 rs192315283 (1) 
  rs76645968 2:53827686 ASB3 G/C 0.977 0.99 0.073   0.014 1.79 x 10-7 
rs76645968 
(0.26), 
rs12328289 
(0.26) 
  rs920065 3:5893776 MRPS35P1/ MRPS36P1 C/G 0.824 0.96 0.028   0.006 4.25 x 10-7 rs920065 
(0.49) 
  rs115320831 4:159178375 TMEM144 A/G 0.702 0.98 0.024   0.005 3.68 x 10-7 rs115320831 (0.58) 
  rs35309287 5:146775386 DPYSL3 TA/T 0.970 0.94 0.067   0.013 1.25 x 10-7 
rs35309287 
(0.45), 
rs34398961 
(0.45) 
  rs189689339 6:82375372 FAM46A T/C 0.003 0.67 0.226   0.044 2.13 x 10-7 rs189689339 
(1) 
  rs17507216 15:83226925 CPEB1 A/G 0.232 1.00 0.026   0.005 1.59 x 10-7 
rs17507216 
(0.20), 
rs72751643 
(0.11) 
  rs73536079 X:67154206 AR/OPHN1 T/G 0.002 0.90 0.634   0.115 3.94 x 10-8 rs73536079 (1) 
  rs182765975* 3:78538431 ROBO1 T/G 0.003 0.86 0.099   0.018 3.33 x 10-8 
rs182765975 
(0.33), 
rs191435135 
(0.33), 
rs182979911 
(0.33) 
  rs142261172** 12:126049981 TMEM132B A/G 0.004 0.92 0.106   0.018 9.06 x 10-9 
rs142261172 
(0.50),  
rs189248622 
(0.50) 
E=effect allele, A=alternative allele, Chr=chromosome, OR=Odds Ratio, CI=confidence interval, INFO=imputation quality from Impute2. EAF=effect allele frequency.  Note, increasing 
beta and Odds Ratio indicate longer sleep duration in hours, increased insomnia symptoms, and increased sleepiness.  Analyses are adjusted for age, sex, genetic ancestry and 
genotyping array.  * denotes secondary analysis with additional adjustment for depression.  **denotes secondary analysis with additional adjustment for body mass index.  Bold denotes 
genome-wide significant signals (p<5x10-8). † Using PICS.   
 426 
Table 2.  Genome-wide significant (p<5x10-8) loci associated with a multiphenotype model of sleep duration, insomnia symptoms, excessive daytime sleepiness and categorical 
chronotype in subjects of European ancestry in the UKBiobank. 
     
SNP Chr:position NCBI 37 
Nearest 
Gene 
Alleles 
(E/A) EAF 
Imputation 
Quality 
Multitrait p-
val  Sleep Duration  Insomnia Symptoms  
Excessive 
Daytime 
Sleepiness 
 Chronotype Causal SNPs (probability) 
        Beta SE  OR 95% CI  Beta SE  Beta SE  
        p-val  p-val  p-val  p-val  
rs12140153 1:62352479 INADL T/G 0.099 0.93 1.06x10-10  -0.009 0.007  1.039 0.999-1.08  -0.036 0.007  0.036 0.008 rs12140153 (1) 
        0.22  0.05  6.60x10-7  2.59x10-6  
rs76681500 1:77247749 AK5 A/G 0.159 0.99 1.03x10-9  -0.002 0.006  0.98 0.950-1.011  -0.008 0.006  -0.043 0.006 rs76681500 (0.5732) 
        0.79  0.27  0.15  1.50x10-12  
rs694383 1:180834827 RGS16 C/G 0.030 1.00 2.72x10-11  0.018 0.012  0.98 0.917-1.048  -0.009 0.012  0.099 0.013 rs694383 (0.2207), rs509476 
(0.2207),  rs1144566 (0.2207), 
rs12743617 (0.2207) 
        0.14  0.75  0.47  2.61x10-14  
rs113851554 2:66523432 MEIS1 T/G 0.056 1.00 3.97x10-16  0.001 0.009  1.264 1.202-1.329  -0.002 0.009  0.033 0.01 rs113851554 (0.9619) 
        0.95  9.11x10-19  0.85  5.64x10-4  
rs62158211 2:113822609 PAX8 T/G 0.214 0.99 8.18x10-13  0.039 0.005  0.943 0.917-0.969  0.005 0.005  0.014 0.005 rs62158211 (0.1547),rs62158213 
(0.1547), rs4618068 (0.1547), 
rs1807282 (0.1547), rs56093896 
(0.1547)   
        4.72x10-14  1.31x10-5  0.37  7.93x10-3  
rs3122163 6:55164327 HCRTR2 T/C 0.768 0.99 4.18x10-10  0.019 0.005  0.984 0.957-1.011  -0.023 0.005  0.021 0.005 rs3122163 (0.0833), rs34694541 
(0.0833), rs3122170 (0.0833) 
        9.97x10-5  0.52  5.51x10-6  8.68x10-5  
E=effect allele, A=alternative allele, Chr=chromosome, OR=Odds Ratio, CI=confidence interval. EAF=effect allele frequency.  Note, increasing beta and Odds Ratio indicate longer sleep 
duration,  increased insomnia symptoms, increased daytime sleepiness, and later chronotype. 
    
Figure 1.  Sleep traits are phenotypically and genetically correlated.    a.  Phenotypic 427 
correlation between the reported sleep traits, using Spearman correlation (r).  b.  Genetic 428 
correlation (rG) between the reported sleep traits, using LD-score regression67.  Color scale 429 
represents the strength of the correlation.  Chronotype ranges from extreme morning types to 430 
extreme evening types.    431 
  432 
 433 
Figure 2. Regional association plots for genome-wide significant loci.  Panel a sleep 434 
duration, b-d insomnia symptoms, e excessive daytime sleepiness, f-g composite trait of sleep 435 
duration, insomnia symptoms, excessive daytime sleepiness, and chronotype.  Chromosomal 436 
position is indicated on the x-axis and –log10 p-values for each SNP (filled circles/squares) is 437 
indicated on the y-axis, with the lead SNP shown in purple (400kb window around lead SNP 438 
shown).  Genes within the region are shown in the lower panel.  The blue line indicates the 439 
recombination rate.  Additional SNPs in the locus are colored according to linkage disequilibrium 440 
(r2) with the lead SNP (estimated by LocusZoom based on the CEU HapMap haplotypes or 441 
within UK Biobank (panel c).  Squares represent directly genotyped SNPs, and circles represent 442 
imputed SNPs.   443 
 444 
  445 
Figure 3.  Partitioning of genetic architecture of sleep duration, insomnia symptoms, and 446 
excessive daytime sleepiness across functional annotation categories. Fold enrichment 447 
estimates for the main annotations of LD-score regression50 are indicated on the y-axis across 448 
functional annotation class on the x-axis for each trait.   Error bars represent the 95% 449 
confidence interval around the estimate.  25 functional annotations were tested, and annotations 450 
passing the multiple testing threshold (p<0.005) are shown.  For context, the average 451 
enrichment across functional annotation categories is shown for 9 traits with significant genetic 452 
correlation to at least one sleep trait (GWAS traits correlated with Sleep: includes GWAS for 453 
BMI, waist circumference, birth weight, depression, educational attainment, three glycemic traits 454 
in non-diabetics, and schizophrenia) or for 5 traits with no significant genetic correlation to any 455 
sleep traits (GWAS traits uncorrelated with Sleep: includes GWAS for Alzheimer’s Disease, 456 
Type 2 Diabetes, autism, rheumatoid arthritis, and height). Abbreviations:  H3K9=histone H3 457 
lysine 9.  458 
 459 
 460 
Figure 4.  Shared genetic architecture between sleep duration, insomnia symptoms, or 461 
excessive daytime sleepiness and 20 behavioral and disease traits. LD-score regression67 462 
estimates of genetic correlation (rG) of sleep duration, insomnia symptoms, and excessive 463 
daytime sleepiness are compared with the summary statistics from 20 publicly available 464 
genome-wide association studies of psychiatric and metabolic disorders, immune diseases, and 465 
other traits of natural variation.  Blue, positive genetic correlation; red, negative genetic 466 
correlation, rg values displayed for significant correlations. Larger squares correspond to more 467 
significant P values.  Genetic correlations that are significantly different from zero after 468 
Bonferroni correction are marked with an asterisk, after Bonferroni correction p-value cut-off is 469 
0.0025.  All genetic correlations in this report can be found in tabular form in Supplementary 470 
Table 12.  Abbreviations: BMI=body mass index, BMD=bone mineral density, HOMA-IR= 471 
Homeostatic model assessment of insulin resistance. * p<10-3, **p<10-5, ***p<10-7.   472 
 473 
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